MPN
Advertisement
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
US veterans who were exposed to Agent Orange have an increased risk of myeloproliferative neoplasms.
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis.
Patients admitted for atrial fibrillation who have myeloproliferative neoplasms have an increased risk of bleeding.
According to Harinder Gill, MD, MBBS, FRCP, FRCPath, there is no optimal treatment strategy established for patients ...
In the phase 2 MANIFEST trial, John Mascarenhas, MD, and colleagues evaluated pelabresib, an oral bromodomain and ...
Studies have shown the JAK2 V617F somatic driver mutation is associated with disease progression in patients with ...
Researchers from the Division of Hematology at Mayo Clinic, led by Naseema Gangat, MBBS, sought to identify predictors ...
Leukemic transformation is a largely fatal event among patients with a myeloproliferative neoplasm (MPN). Previous ...
In previous research, Ph-negative myeloproliferative neoplasms (MPNs) have been associated with autoimmune diseases. ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.